PRODRUGS AND AQUEOUS FORMULATIONS OF DEXANABINOL

Information

• Research Project
• 2038382

• ApplicationId

  2038382

• Core Project Number

  R43NS035382

• Full Project Number

  1R43NS035382-01A1

• Serial Number

  35382

• FOA Number

• Sub Project Id

• Project Start Date

  5/1/1997 - 27 years ago

• Project End Date

  10/31/1997 - 27 years ago

• Program Officer Name

• Budget Start Date

  5/1/1997 - 27 years ago

• Budget End Date

  10/31/1997 - 27 years ago

• Fiscal Year

  1997

• Support Year

  1

• Suffix

  A1

• Award Notice Date

  4/28/1997 - 27 years ago

Organizations

• PHARMOS CORPORATION

DESCRIPTION: (adapted from applicant's abstract) The proposal focuses on the design and synthesis of prodrugs of the NMDA antagonist dexanabinol (HU 211). This compound demonstrates efficacy as an antiischemic agent but may have limited therapeutic potential due to its low water solubility. The objective of the proposal is therefore to derivatize the parent compound with various esters of amino acids containing quaternary or tertiary amines and evaluate them for water and blood stability. Promising candidates will be evaluated for toxicity. Phase II studies will further develop and evaluate prodrug candidates as potential treatment for brain injury.

IC Name

• Activity

  R43

• Administering IC

  NS

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  853

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  ZRG3

• Study Section Name

• Organization Name

  PHARMOS CORPORATION

• Organization Department

• Organization DUNS

• Organization City

  ALACHUA

• Organization State

  FL

• Organization Country

  UNITED STATES

• Organization Zip Code

  32615

• Organization District

  UNITED STATES